Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
mikeelogan

Petitioners Ask To Add 3 Ailments To Medical Marijuana Program - Hartford Courant

Healthiest Foods of All Time (With Recipes)

healthiest foods, health food, diet, nutrition, time.com stock, red wine, alcohol Fabry disease is an inherited condition in which fat builds up in the cells, resulting in hearing loss, gastrointestinal problems, cloudiness in the cornea psoriasis eczema and potentially deadly complications such as kidney damage, heart attack and stroke. Ulcerative colitis is a chronic, inflammatory bowel disease. State law currently allows residents 18 or older to register as medical marijuana patients if they have any of the following conditions: cancer, glaucoma, HIV or AIDS, Parkinson's disease, multiple sclerosis, intractable spasticity related to nerve damage in the spinal cord, epilepsy, cachexia, wasting syndrome, Crohn's disease or post-traumatic stress disorder.
For the original version including any supplementary images or video, visit psoriasis diabetes href='http://www.courant.com/business/hc-medical-marijuana-connecticut-colitis-20150302-story.html?track=rss' >http://www.courant.com/business/hc-medical-marijuana-connecticut-colitis-20150302-story.html?track=rss

Research and Markets: Chronic Plaque Psoriasis Pipeline Review 2015 - Analysis of 20 Companies & 22 Drug Profiles - Yahoo Finance

It may be hard to believe it now, but at one point generic drugs weren't nearly as common as they are today. For example, the generic fill rate, which is the percentage of all prescriptions that are filled with generic drugs, was just 43% in 2002. Today, generic drugs account for about 80% of all prescriptions written, and as a result, generic-drug makers' revenue has skyrocketed. By 2008, the global generic drug market had become worth $81 billion a year,and by 2013 it had eclipsed the $300 billion mark. The rapid adoption of generic drugs has many companies, including Amgen, thinking that a similar multibillion-dollar market may be in the making for generic alternatives to biologic drugs. According to IMS Health, the biologic drugs market is expected to eclipse $200 billion in 2018, and that has industry participants thinking the biosimilars market could be worth as much as $20 billion by 2020. Making a play Amgen is arguably one of the companies most exposed to the threats of biosimilars, but it's also one of the companies best positioned to benefit from them.
For the original version including any supplementary images or video, visit http://www.investopedia.com/articles/markets/030215/amgens-next-big-thing.asp?partner=mediafed

Is This Amgen's Next Big Thing? (AMGN)

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development AbGenomics International, Inc.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/research-markets-chronic-plaque-psoriasis-121800165.html

Cramer suspects that the ripple effects just haven't been that visible in the U.S. economy. He outlined a few data points that clearly mark a difference in what was expected and what actually happened. Considering that most thought an oil crash would cause the market to collapse, Cramer just hasn't seen the pain yet. There are just too many hedges, strong balance sheets and large loan capacities to allow for any real worry. Many companies seem to easily cut back, for now. Maybe we won't endure the oil apocalypse?
For the original version including any supplementary images or video, visit http://www.cnbc.com/id/102461077?__source=yahoonews&par=yahoonews

Amgen's Kyprolis Under EU Review - Analyst Blog - Yahoo Finance

Kyprolis enjoys orphan drug status in the EU and was granted accelerated assessment. According to the company press release, multiple myeloma affects approximately 89,000 people in Europe. Kyprolis, which became a part of Amgen's portfolio following its Oct 2013 acquisition of Onyx, delivered sales of $331 million in 2014.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/amgens-kyprolis-under-eu-review-003612635.html

3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year - NASDAQ.com

Remove and discard stalks. Cut fennel bulb in half lengthwise; discard core. Thinly slice bulbs. Add fronds, fennel slices, and orange sections to bowl; toss gently to combine.
For the original version including any supplementary images or video, visit http://time.com/3724505/50-healthiest-foods/

These stocks galloping along with the llama drama

Over time, Pharmacyclics believes that Imbruvica's addressable patient population across blood cancers could climb from 40,000 people today to more than 374,000. If that happens, then Pharmacyclics EPS should climb nicely over the coming years from the adjusted net income of $1.80 reported in 2014. For example, the average analyst expects that Pharmacyclics' EPS will more than double from current levels, to hit $3.94 in 2016.
For the original version including any supplementary images or video, visit http://www.nasdaq.com/article/3-big-cap-biotechs-that-could-trounce-gilead-sciences-this-year-cm449603

Don't be the product, buy the product!

Schweinderl